The objective of present work was to develop taste masked orodispersible tablets of mirabegron. Mirabegron is beta 3 adrenoceptor agonist used to treat overactive bladder. Overactive bladder (OAB) is defined as a symptom syndrome showing feeling of urgency to urinate, typically accompanied by frequent daytime and nocturnal urination, in the absence of proven infection or other obvious pathology. Over active bladders are generally common in geriatrics. Moreover, this drug has a very strong bitter taste. Frequent dosing requires frequent water intake, which further aggregates the condition of over active bladder and bitter taste of drug affects patient compliance. Hence a need arises to mask the bitter taste for development of an ODT which does not require consuming water with every dosage. In this work, the bitter taste of mirabegron was masked by forming a complex with an ion exchange resin tulsion 344. The drug resin complexation process was optimized for resin activation, drug: resin ratio, soaking time and stirring time. In –vitro release studies revealed complete drug elution from the complex within 10 minutes in pH 1.2 buffer. The taste-masked complex was then formulated into palatable orodispersible tablets using a direct compression approach by use of superdisintegrants to achieve a rapid disintegration. The tablets were evaluated for weight variation, hardness, friability, drug content, wetting time, In- vivo disintegration time and in-vitro dissolution time.
Cite this article:
Sarika S. Malode, Milind P. Wagh. Formulation and Evaluation of Orodispersible Tablets Containing Taste Masked Mirabegron Resinate. Research Journal of Pharmacy and Technology. 2021; 14(9):4736-2. doi: 10.52711/0974-360X.2021.00824
Sarika S. Malode, Milind P. Wagh. Formulation and Evaluation of Orodispersible Tablets Containing Taste Masked Mirabegron Resinate. Research Journal of Pharmacy and Technology. 2021; 14(9):4736-2. doi: 10.52711/0974-360X.2021.00824 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-9-38
1. Pagar HB et al. Taste Masking: A Review. Research Journal of Pharmacy and Technology. 2012; 5(2): 152-157.
2. Chang RK et al. Fast-dissolving tablets. Pharmaceutical Technology. 2000; 24(6): 52-52.
3. Malaak, FA et al. Orodispersible Tablets: Novel Strategies and future challenges in Drug Delivery. Research Journal of Pharmacy and Technology. 2019; 12(11): 5575-5582.
4. Dobetti L. Fast-melting tablets: Developments and Technologies. Pharmaceutical Technology (2001): 44-44.
5. Siddiqui et al. Fast dissolving tablets: preparation, characterization and evaluation: an overview. International Journal of Pharmaceutical Sciences Review and Research. 2010; 4(2): 87-96.
6. SOHI H, Sultana Y, Khar R. 2004. Taste Masking Technologies in Oral Pharmaceuticals: Recent Developments and Approaches. Drug Dev. Ind. Pharm.2004; 30(5): 429-448.
7. Agarwal R Rohit M, Amarjit S. Studies of ion-exchange resin complex of chloroquine phosphate. Drug Development and Industrial Pharmacy. 2000; 26(7): 773-776.
8. Manek SP Kamat VS. Evaluation of Indion CRP-244 and CRP-254 as sustained release and taste masking agents. Indian J. Pharm. Sci. 1981; 43(11-12): 209-212.
9. Honeysett RA et al. Taste-masked Buflomedil preparation. Eur. Pat. Appl. EP0501763. 1992.
10. Amita N, Garg S. An update on taste masking technologies for oral pharmaceuticals. Indian Journal of Pharmaceutical Sciences. 2002; 64(1): 10.
11. Bhide AA et al. Mirabegron–a selective β3-adrenoreceptor agonist for the treatment of overactive bladder. Research and Reports in Urology. 2012: 41.
12. Kasashima Y et al. 2015. U.S. Patent Application No. 14/388,099.
13. Tejas K, Deshmukh G. A Review on Orodispersible Tablets: A Novel Approach. Research Journal of Pharmacy and Technology. 2019; 12(8): 3993-4001.
14. Borodkin S , Dean PS. Polycarboxylic acid ion‐exchange resin adsorbates for taste coverage in chewable tablets. Journal of Pharmaceutical Sciences.1971; 60(10): 1523-1527.
15. Aulton ME, Taylor K. Pharmaceutics-The science of dosage form design, Churchill Livingstone. London, England. 2002: 340-348.
16. Martin A. Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences. BI Waverly. Pvt Ltd, 1993.
17. More SA and Shrinivas KM. Formulation Development and Evaluation of Orodispersible Tablet of Omeprazole by Using Co-Processed Superdisintegrant. Research Journal of Pharmaceutical Dosage Forms and Technology. 2012; 4(4): 216-220.
18. Cohen JL. The Official compendia of standards. The United States Pharmacopeia (USP 24 NF 19). The United States Pharmocopedial Convention Press, 1975.
19. Das PS and Puja S. Development and Optimization of Orodispersible Tablets of Serotonin Hydrochloride. Research Journal of Pharmaceutical Dosage Forms and Technology. 2018; 10(1): 13-16.
20. Redkar MR, Gore SP, Devrajan PV. D-Zolv: Taste masked mouth dissolving tablet. Indian J Pharm Sci. 2002; 64(3): 291-292.
21. Sahu SK et al. Formulation and evaluation of orodispersible tablet of montelukast sodium. Research Journal of Pharmacy and Technology. 2018; 11(3): 1112-1118.